Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 5/2023

07.03.2023

Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review

verfasst von: Sam Dowthwaite, James Jackson, Marcin Dzienis, Eric Khoo, Mathew Cronin, Emily Guazzo

Erschienen in: Current Oncology Reports | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review the impact of contemporary treatment strategies on salvage outcomes in patients with recurrent human papilloma virus-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC).

Recent Findings

Secondary to HPV, changes in disease biology have impacted primary treatments and subsequent approaches to patients with recurrence. With treatment strategies more inclusive of upfront surgery, the characteristics of patients with recurrence HPV + OPSCC have been further redefined. Less invasive endoscopic surgical approaches such as transoral robotic surgery (TORS), and the continued refinement of conformal radiotherapy techniques, have improved treatment options for patients with recurrent HPV + OPSCC. Systemic treatment options have continued to expand including potentially effective immune-based therapies. Effective surveillance with systemic and oral biomarkers offers hope of earlier detection of recurrence.

Summary

Management of patients with recurrent OPSCC remains difficult. Modest improvements in salvage treatment have been observed within the HPV + OPSCC cohort largely reflecting disease biology and improved treatment techniques.
Literatur
1.
Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J Natl Cancer Inst. 2015;107(12):djv344.PubMedCrossRef
2.
Liao CI, Francoeur AA, Kapp DS, Caesar MAP, Huh WK, Chan JK. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001–2017. JAMA Netw Open. 2022;5(3): e222530.PubMedPubMedCentralCrossRef
3.
Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated cancers - United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918–24.PubMedPubMedCentralCrossRef
4.
Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Villaret DB, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94(11):2967–80.PubMedCrossRef
5.
Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40.PubMedCrossRef
6.
Sung SY, Kim YS, Kim SH, Lee SJ, Lee SW, Kwak YK. Current evidence of a deintensification strategy for patients with hpv-related oropharyngeal cancer. Cancers (Basel). 2022;14(16):3969.PubMedCrossRef
7.
Lin BM, Wang H, D’Souza G, Zhang Z, Fakhry C, Joseph AW, et al. Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer. 2013;119(19):3462–71.PubMedCrossRef
8.
Sinha P, Lewis JS Jr, Piccirillo JF, Kallogjeri D, Haughey BH. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer. 2012;118(14):3519–30.PubMedCrossRef
9.
Carey RM, Brody RM, Shimunov D, Shinn JR, Mady LJ, Rajasekaran K, et al. Locoregional recurrence in p16-positive oropharyngeal squamous cell carcinoma after TORS. Laryngoscope. 2021;131(12):E2865–73.PubMedCrossRef
10.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):7348.PubMedPubMedCentralCrossRef
11.
Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25(30):4800–5.PubMedCrossRef
12.
Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281–8.PubMedCrossRef
13.
Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008;26(34):5518–23.PubMedCrossRef
14.
Vargo JA, Kubicek GJ, Ferris RL, Duvvuri U, Johnson JT, Ohr J, et al. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer. Laryngoscope. 2014;124(7):1579–84.PubMedCrossRef
15.
Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119(2):153–9.PubMedPubMedCentralCrossRef
16.
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736–47.PubMedCrossRef
17.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.PubMedPubMedCentralCrossRef
18.
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.PubMedCrossRef
19.
Benchetrit L, Torabi SJ, Givi B, Haughey B, Judson BL. Prognostic significance of extranodal extension in HPV-mediated oropharyngeal carcinoma: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2021;164(4):720–32.PubMedCrossRef
20.
Liu HY, Daniels CP, Trada Y, Bernard A, You KH, Brown E, et al. The importance of smoking status at diagnosis in human papillomavirus-associated oropharyngeal cancer. Head Neck. 2021;43(5):1440–50.PubMedCrossRef
21.
Spector ME, Gallagher KK, Light E, Ibrahim M, Chanowski EJ, Moyer JS, et al. Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck. 2012;34(12):1727–33.PubMedPubMedCentralCrossRef
22.
Philips R, Sagheer H, Barsouk A, Swendseid B, Johnson J, Bar AdV, et al. Trends in adjuvant therapy after surgery for oropharyngeal squamous cell carcinoma. Laryngoscope. 2022;132(4):806–12.PubMedCrossRef
23.
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol. 2022;40(8):866–75 The ORATOR trial was the first randomized control trial aimed at determining whether primary surgery offered improved outcomes over radiotherapy / chemoradiotherapy in patients with early stage HPV+OPSCC.PubMedCrossRef
24.
Ochoa E, Stanford-Moore G, Fakhry C, Ryan WR. Predicting adverse histopathology and need for postsurgical adjuvant therapy for human papilloma virus-associated oropharynx carcinoma. Otolaryngol Head Neck Surg. 2021;165(2):309–16.PubMedCrossRef
25.
Machczyński P, Majchrzak E, Niewinski P, Marchlewska J, Golusiński W. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277(9):2407–12.PubMedPubMedCentralCrossRef
26.
• Ryan WR, Xu MJ, Ochoa E, Plonowska-Hirschfeld KA, Zebolsky AL, Ha PK, et al. Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: a 12-institution study of 344 patients. Cancer. 2021;127(17):3092–106. This large multi institutional trial demonstrated favourable oncologic outcomes amongst a cohort of HPV+OPSCC patients undergoing surgery-only treatment, with high rates of successful salvage treatment in those who developed recurrent disease.PubMedCrossRef
27.
Dowthwaite S, Panizza B, O’Neill J, Porceddu S, Jackson JE, Chua B. Outcomes of primary trans-oral surgical management of early tonsillar squamous cell carcinoma with risk-adapted adjuvant radiotherapy. Aust J Otolaryngol. 2019;2.
28.
•• Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311). J Clin Oncol. 2022;40(2):138–49. E3311 trial is a large phase 2 trial designed to assess the oncologic safety of deintensified adjuvant radiotherapy in patients with HPV+OPSCC treated with primary surgery. This study demonstrated excellent oncologic outcomes and impressive functional outcomes in this patient cohort.PubMedCrossRef
29.
Owadally W, Hurt C, Timmins H, Parsons E, Townsend S, Patterson J, et al. PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer. 2015;15:602.PubMedPubMedCentralCrossRef
30.
Xu MJ, Plonowska KA, Gurman ZR, Humphrey AK, Ha PK, Wang SJ, et al. Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. Laryngoscope. 2020;130(2):E48-e56.PubMedCrossRef
31.
Thankappan K, Battoo AJ, Vidhyadharan S, Kudpaje A, Balasubramanian D, Iyer S. Economic evaluations comparing tran-oral robotic surgery and radiotherapy in oropharyngeal squamous cell carcinoma: A systematic review. Eur J Surg Oncol. 2021;47(12):2961–70.PubMedCrossRef
32.
Sims JR, Van Abel K, Martin EJ, Lohse CM, Price DL, Olsen KD, et al. Management of recurrent and metastatic HPV-positive oropharyngeal squamous cell carcinoma after transoral robotic surgery. Otolaryngol Head Neck Surg. 2017;157(1):69–76.PubMedCrossRef
33.
Brody RM, Shimunov D, Cohen RB, Lin A, Lukens JN, Hartner L, et al. A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers. Oral Oncol. 2022;127: 105798.PubMedPubMedCentralCrossRef
34.
Cramer JD, Ferris RL, Kim S, Duvvuri U. Primary surgery for human papillomavirus-associated oropharyngeal cancer: survival outcomes with or without adjuvant treatment. Oral Oncol. 2018;87:170–6.PubMedPubMedCentralCrossRef
35.
Smith AW, Gallitto M, Lehrer EJ, Wasserman I, Gupta V, Sharma S, et al. Redefining risk of contralateral cervical nodal disease in early stage oropharyngeal cancer in the human papillomavirus era. Head Neck. 2021;43(5):1409–14.PubMedCrossRef
36.
Kang JJ, Yu Y, Chen L, Zakeri K, Gelblum DY, McBride SM, et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin. 2022.
37.
Jackson RS, Sinha P, Zenga J, Kallogjeri D, Suko J, Martin E, et al. Transoral resection of human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx: outcomes with and without adjuvant therapy. Ann Surg Oncol. 2017;24(12):3494–501.PubMedPubMedCentralCrossRef
38.
Plonowska KA, Strohl MP, Wang SJ, Ha PK, George JR, Heaton CM, et al. Human papillomavirus-associated oropharyngeal cancer: patterns of nodal disease. Otolaryngol Head Neck Surg. 2019;160(3):502–9.PubMedCrossRef
39.
Tirelli G, Gardenal N, Zanelli E, Borsetto D, Phillips V, Marcuzzo AV, et al. Prevalence and prognostic impact of retropharyngeal lymph nodes metastases in oropharyngeal squamous cell carcinoma: Meta-analysis of published literature. Head Neck. 2022;44(10):2265–76.PubMedPubMedCentralCrossRef
40.
Tang C, Komakula S, Chan C, Murphy JD, Jiang W, Kong C, et al. Radiologic assessment of retropharyngeal node involvement in oropharyngeal carcinomas stratified by HPV status. Radiother Oncol. 2013;109(2):293–6.PubMedCrossRef
41.
Bussels B, Hermans R, Reijnders A, Dirix P, Nuyts S, Van den Bogaert W. Retropharyngeal nodes in squamous cell carcinoma of oropharynx: incidence, localization, and implications for target volume. Int J Radiat Oncol Biol Phys. 2006;65(3):733–8.PubMedCrossRef
42.
Gunn GB, Debnam JM, Fuller CD, Morrison WH, Frank SJ, Beadle BM, et al. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer. 2013;119(17):3162–9.PubMedCrossRef
43.
Dirix P, Nuyts S, Bussels B, Hermans R, Van den Bogaert W. Prognostic influence of retropharyngeal lymph node metastasis in squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2006;65(3):739–44.PubMedCrossRef
44.
Kao SS, Ooi EH. Survival outcomes following salvage surgery for oropharyngeal squamous cell carcinoma: systematic review. J Laryngol Otol. 2018;132(4):299–313.PubMedCrossRef
45.
Gilbert H, Kagan AR. Recurrence patterns in squamous cell carcinoma of the oral cavity, pharynx, and larynx. J Surg Oncol. 1974;6(5):357–80.PubMedCrossRef
46.
Zafereo ME, Hanasono MM, Rosenthal DI, Sturgis EM, Lewin JS, Roberts DB, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009;115(24):5723–33.PubMedCrossRef
47.
Bachar GY, Goh C, Goldstein DP, O’Sullivan B, Irish JC. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol. 2010;267(2):295–301.PubMedCrossRef
48.
Patel TR, Lee S, Tajudeen BA, Stenson K, Bhayani M, Al-Khudari S. Association of HPV status with survival after surgical salvage of oropharyngeal cancers. Am J Otolaryngol. 2022;43(4): 103491.PubMedCrossRef
49.
Röösli C, Studer G, Stoeckli SJ. Salvage treatment for recurrent oropharyngeal squamous cell carcinoma. Head Neck. 2010;32(8):989–96.PubMedCrossRef
50.
Richey LM, Shores CG, George J, Lee S, Couch MJ, Sutton DK, et al. The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg. 2007;136(1):98–103.PubMedCrossRef
51.
Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 Pt 2 Suppl 93):1–18.PubMedCrossRef
52.
Christopherson KM, Moreno AC, Elgohari B, Gross N, Ferrarotto R, Mohamed ASR, et al. Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021;113: 105125.PubMedCrossRef
53.
Sivarajah S, Isaac A, Cooper T, Zhang H, Puttagunta L, Abele J, et al. Association of fludeoxyglucose F 18-labeled positron emission tomography and computed tomography with the detection of oropharyngeal cancer recurrence. JAMA Otolaryngol Head Neck Surg. 2018;144(11):1037–43.PubMedPubMedCentralCrossRef
54.
de Ridder M, Gouw ZAR, Navran A, Hamming-Vrieze O, Jasperse B, van den Brekel MWM, et al. FDG-PET/CT improves detection of residual disease and reduces the need for examination under anaesthesia in oropharyngeal cancer patients treated with (chemo-)radiation. Eur Arch Otorhinolaryngol. 2019;276(5):1447–55.PubMedCrossRef
55.
Chung MJ, Kim YS, Kim JY, Lee YH, Jang JH, Kang JH, et al. Predictors of distant metastasis after radical surgery followed by postoperative radiotherapy with or without chemotherapy for oropharyngeal cancer. Cancer Res Treat. 2016;48(4):1167–76.PubMedPubMedCentralCrossRef
56.
White H, Ford S, Bush B, Holsinger FC, Moore E, Ghanem T, et al. Salvage surgery for recurrent cancers of the oropharynx: comparing TORS with standard open surgical approaches. JAMA Otolaryngol Head Neck Surg. 2013;139(8):773–8.PubMedCrossRef
57.
Davis KS, Vargo JA, Ferris RL, Burton SA, Ohr JP, Clump DA, et al. Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history. Oral Oncol. 2014;50(11):1104–8.PubMedPubMedCentralCrossRef
58.
Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32(30):3365–73.PubMedPubMedCentralCrossRef
59.
• Bagley AF, Garden AS, Reddy JP, Moreno AC, Frank SJ, Rosenthal DI, et al. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020;42(11):3326–35. Large volume, single institutional experience with reirradiation in patients with recurrent OPSCC demonstrating acceptable local control with highly conformal techniques. Risk of late toxicities remains high.PubMedPubMedCentralCrossRef
60.
Caudell JJ, Ward MC, Riaz N, Zakem SJ, Awan MJ, Dunlap NE, et al. Volume, dose, and fractionation considerations for imrt-based reirradiation in head and neck cancer: a multi-institution analysis. Int J Radiat Oncol Biol Phys. 2018;100(3):606–17.PubMedCrossRef
61.
Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, et al. Phase II trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022;28(16):3464–72.PubMedPubMedCentralCrossRef
62.
63.
Huang SH, O’Sullivan B, Xu W, Zhao H, Chen DD, Ringash J, et al. Temporal nodal regression and regional control after primary radiation therapy for N2–N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys. 2013;87(5):1078–85.PubMedCrossRef
64.
Vainshtein JM, Spector ME, Stenmark MH, Bradford CR, Wolf GT, Worden FP, et al. Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014;50(3):234–9.PubMedCrossRef
65.
Sjövall J, Chua B, Pryor D, Burmeister E, Foote MC, Panizza B, et al. Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy. Oral Oncol. 2015;51(3):260–6.PubMedCrossRef
66.
Chan JY, Sanguineti G, Richmon JD, Marur S, Gourin CG, Koch W, et al. Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138(11):1040–6.PubMedPubMedCentralCrossRef
67.
Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, et al. Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit Rev Oncol Hematol. 2016;108:40–51.PubMedCrossRef
68.
Rulach R, Zhou S, Hendry F, Stobo D, James A, Dempsey MF, et al. 12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers. Oral Oncol. 2019;97:76–81.PubMedCrossRef
69.
Wotman M, Ghaly M, Massaro L, Tham T, Seetharamu N, Kamdar D, et al. Improving post-CRT neck assessment in patients with HPV-associated OPSCC (Review). Mol Clin Oncol. 2020;13(4):24.PubMedPubMedCentral
70.
71.
Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011;33(12):1675–82.PubMedCrossRef
72.
Prestwich RJD, Arunsingh M, Zhong J, Dyker KE, Vaidyanathan S, Scarsbrook AF. Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma. Eur Radiol. 2020;30(2):1212–20.PubMedCrossRef
73.
Donatelli-Lassig AA, Duffy SA, Fowler KE, Ronis DL, Chepeha DB, Terrell JE. The effect of neck dissection on quality of life after chemoradiation. Otolaryngol Head Neck Surg. 2008;139(4):511–8.PubMedCrossRef
74.
Lavertu P, Bonafede JP, Adelstein DJ, Saxton JP, Strome M, Wanamaker JR, et al. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124(4):401–6.PubMedCrossRef
75.
Fu TS, Scheffler P, Forner D, Noel CW, Huang SH, Gilbert RW, et al. A cost-utility analysis comparing CT surveillance, PET-CT surveillance, and planned postradiation neck dissection for advanced nodal HPV-positive oropharyngeal cancer. Cancer. 2021;127(18):3372–80.PubMedCrossRef
76.
van der Putten L, van den Broek GB, de Bree R, van den Brekel MW, Balm AJ, Hoebers FJ, et al. Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head Neck. 2009;31(5):593–603.PubMedCrossRef
77.
Pellini R, Manciocco V, Turri-Zanoni M, Vidiri A, Sanguineti G, Marucci L, et al. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease. J Craniomaxillofac Surg. 2014;42(8):1834–9.PubMedCrossRef
78.
Connor S, Sit C, Anjari M, Szyszko T, Dunn J, Pai I, et al. Correlations between DW-MRI and (18) F-FDG PET/CT parameters in head and neck squamous cell carcinoma following definitive chemo-radiotherapy. Cancer Rep (Hoboken). 2021;4(4): e1360.PubMed
79.
Lee JY, Garcia-Murillas I, Cutts RJ, De Castro DG, Grove L, Hurley T, et al. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer. 2017;117(6):876–83.PubMedPubMedCentralCrossRef
80.
• Berger BM, Hanna GJ, Posner MR, Genden EM, Lautersztain J, Naber SP, et al. Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. Clin Cancer Res. 2022;28(19):4292–301. Retrospective analysis of over a thousand consecutive patients treated for HPV+OPSCC who underwent post-treatment surveillance including testing for circulating tumour tissue modified viral-HPV DNA. Potential role demonstrated in this cohort to assist detection of early recurrence that may help guide future salvage treatment strategies.PubMedPubMedCentralCrossRef
Metadaten
Titel
Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review
verfasst von
Sam Dowthwaite
James Jackson
Marcin Dzienis
Eric Khoo
Mathew Cronin
Emily Guazzo
Publikationsdatum
07.03.2023
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 5/2023
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-023-01386-5

Weitere Artikel der Ausgabe 5/2023

Current Oncology Reports 5/2023 Zur Ausgabe

ReviewPaper

Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions

ReviewPaper

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

ReviewPaper

Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN)

ReviewPaper

Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment

ReviewPaper

Clonal Hematopoiesis and the Heart: a Toxic Relationship

ReviewPaper

Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise